SCHEMBL4345948

SCHEMBL4345948

O=C(NCc1ccccc1)Nc1cccc(Cl)c1O

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.62
GSK3B P49841 1/20 0.62
CFD P00746 1/20 0.60
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
RAB9A P51151 1/20 0.56
TRPV1 Q8NER1 1/20 0.56
ALDH1A1 P00352 5/20 0.56
MAPK1 P28482 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
GAA P10253 1/20 0.55
POLB P06746 2/20 0.54
LMNA P02545 1/20 0.54
CA12 O43570 2/20 0.54
CA1 P00915 2/20 0.54
CA2 P00918 2/20 0.54
CA9 Q16790 2/20 0.54
MAPT P10636 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27942165 0.88 CFD (0.67) KDM4EGSK3BCFDMEN1KMT2A
SCHEMBL4360010 0.86 SMN1; SMN2 (0.64) MEN1KMT2ARAB9ATRPV1ALDH1A1
SCHEMBL5604191 0.84 CXCR1 (0.58) KDM4EGSK3BCFDMEN1KMT2A
SCHEMBL4357504 0.84 TRPV1 (0.61) MEN1KMT2ARAB9ATRPV1MAPT
SCHEMBL4353325 0.83 CA12 (0.55) KDM4EGSK3BCFDMEN1KMT2A
SCHEMBL4347160 0.82 KDM4E (0.62) KDM4EGSK3BCFDMEN1KMT2A
SCHEMBL4341984 0.82 GAA (0.65) KDM4EMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL7860840 0.82 KDM4E (0.58) KDM4EGSK3BCFDMEN1KMT2A
SCHEMBL1514314 0.81 KDM4E (0.84) KDM4EGSK3BCFDMEN1KMT2A
SCHEMBL4347130 0.81 RAB9A (0.60) MEN1KMT2ARAB9AALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
CN-100546977-C Suppress the new compound and the application thereof of rotamase JERINI AG (DE) 2009-10-07 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 KDM4E 2662/4885GSK3B 2056/4885CFD 3650/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 KDM4E 1689/4885GSK3B 1707/4885CFD 4392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.